​
​

Avidity Biosciences (RNA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Avidity Biosciences Revenue Highlights

Latest Revenue (Y)

$9.56M

Latest Revenue (Q)

$2.04M

Avidity Biosciences Revenue by Period

Avidity Biosciences Revenue by Year

DateRevenueChange
2023-12-31$9.56M3.64%
2022-12-31$9.22M-1.09%
2021-12-31$9.33M37.41%
2020-12-31$6.79M192.67%
2019-12-31$2.32M511.87%
2018-12-31$379.00K-

Avidity Biosciences generated $9.56M in revenue during NA 2023, up 3.64% compared to the previous quarter, and up 2522.43% compared to the same period a year ago.

Avidity Biosciences Revenue by Quarter

DateRevenueChange
2024-06-30$2.04M-42.28%
2024-03-31$3.54M61.56%
2023-12-31$2.19M-22.18%
2023-09-30$2.82M21.68%
2023-06-30$2.32M3.72%
2023-03-31$2.23M-19.36%
2022-12-31$2.77M11.56%
2022-09-30$2.48M13.96%
2022-06-30$2.18M21.34%
2022-03-31$1.79M-3.08%
2021-12-31$1.85M-14.38%
2021-09-30$2.16M-17.03%
2021-06-30$2.61M-3.59%
2021-03-31$2.70M26.24%
2020-12-31$2.14M22.68%
2020-09-30$1.75M13.30%
2020-06-30$1.54M13.48%
2020-03-31$1.36M-6.02%
2019-12-31$1.45M122.31%
2019-09-30$650.00K190.18%
2019-06-30$224.00K100.00%
2019-03-31--

Avidity Biosciences generated $2.04M in revenue during Q2 2024, up -42.28% compared to the previous quarter, and up 91.58% compared to the same period a year ago.

Avidity Biosciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$78.50M$102.40M
PTGXProtagonist Therapeutics$60.00M$4.67M
RLAYRelay Therapeutics$25.55M-
RVMDRevolution Medicines, Inc. Warrant$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
STOKStoke Therapeutics$8.78M$4.89M
SWTXSpringWorks Therapeutics$5.45M$59.73M
IGMSIGM Biosciences$2.13M$516.00K
PLRXPliant Therapeutics$1.58M-
BCELAtreca$770.00K$80.00K
CGEMCullinan Oncology--
BDTXBlack Diamond Therapeutics--
DAWNDay One Biopharmaceuticals-$20.07M
CERECerevel Therapeutics--
PASGPassage Bio--
MLYSMineralys Therapeutics--
AKROAkero Therapeutics--

RNA Revenue FAQ

What is Avidity Biosciences’s yearly revenue?

Avidity Biosciences's yearly revenue for 2023 was $9.56M, representing an increase of 3.64% compared to 2022. The company's yearly revenue for 2022 was $9.22M, representing a decrease of -1.09% compared to 2021. RNA's yearly revenue for 2021 was $9.33M, representing an increase of 37.41% compared to 2020.

What is Avidity Biosciences’s quarterly revenue?

Avidity Biosciences's quarterly revenue for Q2 2024 was $2.04M, a -42.28% decrease from the previous quarter (Q1 2024), and a -11.70% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $3.54M, a 61.56% increase from the previous quarter (Q4 2023), and a 58.67% increase year-over-year (Q1 2023). RNA's quarterly revenue for Q4 2023 was $2.19M, a -22.18% decrease from the previous quarter (Q3 2023), and a -20.80% decrease year-over-year (Q4 2022).

What is Avidity Biosciences’s revenue growth rate?

Avidity Biosciences's revenue growth rate for the last 3 years (2021-2023) was 2.51%, and for the last 5 years (2019-2023) was 312.25%.